Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RNAi Therapeutic”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Enrolling By InvitationNCT06679946
What this trial is testing

Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Alnylam Pharmaceuticals 700
Testing effectiveness (Phase 2)Study completedNCT02292186
What this trial is testing

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 25
Very early researchEnded earlyNCT01153646
What this trial is testing

Gene Transfer for HIV Using Autologous T Cells

Who this might be right for
HIV-1 Infection
City of Hope Medical Center 5
Large-scale testing (Phase 3)Study completedNCT02319005
What this trial is testing

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Who this might be right for
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)Amyloidosis, HereditaryAmyloid Neuropathies, Familial+3 more
Alnylam Pharmaceuticals 206
Testing effectiveness (Phase 2)Active Not RecruitingNCT06659640
What this trial is testing

Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Who this might be right for
Hereditary Hemorrhagic Telangiectasia
Alnylam Pharmaceuticals 89
Not applicableApproved For MarketingNCT02939820
What this trial is testing

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

Who this might be right for
TTR-mediated AmyloidosisAmyloidosis, HereditaryAmyloid Neuropathies, Familial+3 more
Alnylam Pharmaceuticals
Early research (Phase 1)Study completedNCT01814839
What this trial is testing

A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 85
Large-scale testing (Phase 3)Study completedNCT03417102
What this trial is testing

Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

Who this might be right for
Hemophilia AHemophilia B
Genzyme, a Sanofi Company 60
Large-scale testing (Phase 3)Study completedNCT04152200
What this trial is testing

Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1

Who this might be right for
Primary Hyperoxaluria Type 1Primary Hyperoxaluria
Alnylam Pharmaceuticals 21
Early research (Phase 1)Study completedNCT02797847
What this trial is testing

A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

Who this might be right for
Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)
Alnylam Pharmaceuticals 80
Not applicableNo Longer AvailableNCT05505838
What this trial is testing

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin-mediated Amyloidosis With CardiomyopathyATTR Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT02554773
What this trial is testing

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

Who this might be right for
Hemophilia AHemophilia B
Genzyme, a Sanofi Company 34
Testing effectiveness (Phase 2)Study completedNCT01961921
What this trial is testing

The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 27
Large-scale testing (Phase 3)Study completedNCT01960348
What this trial is testing

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Who this might be right for
TTR-mediated AmyloidosisAmyloidosis, HereditaryAmyloid Neuropathies, Familial+3 more
Alnylam Pharmaceuticals 225
Large-scale testing (Phase 3)Study completedNCT03681184
What this trial is testing

Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Who this might be right for
Primary Hyperoxaluria Type 1 (PH1)
Alnylam Pharmaceuticals 39
Testing effectiveness (Phase 2)Study completedNCT02250612
What this trial is testing

SYL040012, Treatment for Open Angle Glaucoma

Who this might be right for
Open Angle GlaucomaOcular Hypertension
Sylentis, S.A. 184
Early research (Phase 1)Study completedNCT01747148
What this trial is testing

Testing the AVI-7100 Flu Drug in Healthy Volunteers

Who this might be right for
Influenza
National Institute of Allergy and Infectious Diseases (NIAID) 66
Early research (Phase 1)Study completedNCT02053454
What this trial is testing

The Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers

Who this might be right for
Transthyretin (TTR)-Mediated Amyloidosis
Alnylam Pharmaceuticals 12
Early research (Phase 1)Study completedNCT02314442
What this trial is testing

An Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Who this might be right for
Hypercholesterolemia
Alnylam Pharmaceuticals 70
Large-scale testing (Phase 3)Study completedNCT03997383
What this trial is testing

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Who this might be right for
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Alnylam Pharmaceuticals 360
Next Page